PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
9.51%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.04%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
7.27%
Gross profit growth of 7.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight advantage that could be built upon.
-21.53%
Negative EBIT growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-21.53%
Negative operating income growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
12.27%
Net income growth of 12.27% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
16.96%
EPS growth of 16.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
16.96%
Diluted EPS growth of 16.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
5.73%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
5.73%
Diluted share growth above 2x Drug Manufacturers - Specialty & Generic median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-91.95%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-81.39%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
233.46%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.90%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
-47.78%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 11.47%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-1691.31%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-637.63%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 40.56%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-556.05%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 36.27%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-5853.83%
Negative 10Y net income/share CAGR vs. Drug Manufacturers - Specialty & Generic median of 32.92%. Seth Klarman might see a fundamental problem if peers maintain growth.
-133.36%
Negative 5Y CAGR while Drug Manufacturers - Specialty & Generic median is 52.52%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
82.42%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 33.87%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
5683.87%
Equity/share CAGR of 5683.87% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-29.32%
Negative 5Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-23.00%
Negative 3Y equity/share growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.38%
AR growth of 10.38% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
8.89%
Inventory growth of 8.89% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
-1.63%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-5.64%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-5.92%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-29.11%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
7.54%
SG&A growth of 7.54% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.